MRP
JANX icon

Measured Risk Portfolios’s Janux Therapeutics JANX Stock Holding History

Measured Risk Portfolios’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-400
Closed -$21.4K – 181
2024
Q4 		$21.4K Buy
+400
New +$21.2K 0.02% 128

Other funds holding JANX

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Logos Global Management
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Measured Risk Portfolios's JANX Position: Q1 2025 in Review

Measured Risk Portfolios sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 400 shares — an estimated $21.4K sold.

Measured Risk Portfolios first reported a position in JANX in Q4 2024 and held it in 1 quarter. The position peaked at $21.4K in Q4 2024. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

  • Measured Risk Portfolios reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Measured Risk Portfolios sold 400 Janux Therapeutics shares in Q1 2025, an estimated $21.4K.
  • Measured Risk Portfolios first reported a position in Janux Therapeutics in Q4 2024 and held it in 1 quarter.
  • Measured Risk Portfolios's Janux Therapeutics position peaked at $21.4K in Q4 2024.
  • 181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on Measured Risk Portfolios's 13F filing for Q1 2025, filed 13 May 2025.